RHEUMATOID ARTHRITIS (RA) DRUGS MARKET 2017-2027 : Trends, Progress and Revenue Forecasting: Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra and Biosimilars; Assessment of Leading Companies Including AbbVie, Roche, J&J, Amgen, Pfizer and Merck & Co.; Prediction of Leading National Markets; and Investigation of Late-Stage R&D Including IL-6, JAK, BTK and GM-CSF Inhibitors

関節リウマチ(RA)治療薬の世界市場2017-2027

◆タイトル:RHEUMATOID ARTHRITIS (RA) DRUGS MARKET 2017-2027 : Trends, Progress and Revenue Forecasting: Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra and Biosimilars; Assessment of Leading Companies Including AbbVie, Roche, J&J, Amgen, Pfizer and Merck & Co.; Prediction of Leading National Markets; and Investigation of Late-Stage R&D Including IL-6, JAK, BTK and GM-CSF Inhibitors
◆商品コード:VGAIN712055
◆調査・発行会社:visiongain
◆発行日:2017年11月
◆ページ数:183
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥379,848見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥455,848見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥759,848見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

visiongain社が発行した当調査レポートでは、関節リウマチ(RA)治療薬の世界市場について調査・分析し、関節リウマチ(RA)治療薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・関節リウマチ(RA)治療薬の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・関節リウマチ(RA)治療薬の世界市場:セグメント別市場分析
・関節リウマチ(RA)治療薬の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

• Do you need definitive Rheumatoid Arthritis market data?
• Succinct Rheumatoid Arthritis market analysis?
• Technological insight?
• Clear competitor analysis?
• Actionable business recommendations?

Read on to discover how this definitive report can transform your own research and save you time.

The introduction of new biologic drugs in Rheumatoid Arthritis, has led Visiongain to publish this timely report. The Rheumatoid Arthritis Drugs market is expected to flourish in the next few years because of rise to prominence of biosimilars that provides a way of reducing the cost of treatment for patients. In addition, the arrival of new JAK inhibitors and BTK inhibitors could provide patients with oral treatments rather than taking their medications intravenously. The expected increases in efficacy are expected to feed through in the latter part of the decade driving growth to new heights. If you want to be part of this growing industry, then read on to discover how you can maximise your investment potential.

Report highlights

• 135 quantitative tables, charts, and graphs across 183 pages

• Analysis of key players in Rheumatoid Arthritis Market
• AbbVie Pharmaceuticals
• Roche Pharmaceuticals
• Johnson & Johnson
• Amgen
• Pfizer
• Merck and Co.
• BMS
• UCB

• Global Rheumatoid Arthritis market outlook and analysis from 2017-2027

• Global Rheumatoid Arthritis Drugs forecasts and analysis from 2017-2027
• Major Biologics drugs forecast 2017-2027
• Major non-biologics drugs forecast 2017-2027
• Leading drugs forecast 2017-2027

• Regional Rheumatoid Arthritis market forecasts from 2017-2027
• US forecast 2017-2027,
• Japan forecast 2017-2027
• India forecast 2017-2027
• Germany forecast 2017-2027
• UK forecast 2017-2027
• France forecast 2017-2027
• Italy forecast 2017-2027
• Spain forecast 2017-2027
• Brazil forecast 2017-2027
• Russia forecast 2017-2027
• China forecast 2017-2027

Key questions answered
• What does the future hold for the Pharmaceutical industry with regards to RA?
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?

Target audience
• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Banks

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

【レポートの目次】

1. Report Overview
1.1 Rheumatoid Arthritis Overview
1.2 Rheumatoid Arthritis Market Segmentation
1.3 Why You Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by this Report
1.6 Who is this Report for?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQ)
1.9 Some Associated Reports
1.10 About Visiongain

2. What is Rheumatoid Arthritis?
2.1 What Causes Rheumatoid Arthritis?
2.2 How Does the Disease Develop?
2.3 How Can It Be Monitored?
2.4 Can RA Be Cured?
2.5 Performance Criteria Used in Clinical Trials
2.5.1 ACR Criteria For Drug Efficacy
2.5.2 HAQ-DI Measures Daily Activities
2.5.3 mSS Assesses Disease on X-Ray
2.5.4 DAS28 For Disease Severity
2.6 How is RA Treated?
2.6.1 Biologic DMARDs Are the Dominant Source of Revenue
2.6.2 Synthetic DMARDs are the Mainstay of Treatment
2.6.3 Others
2.6.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
2.6.3.2 Corticosteroids for Rapid Anti-Inflammatory Effect
2.6.3.3 Analgesics for Rapid Pain Relief
2.7 Comorbid Conditions Associated with RA
2.8 Prevalence and Incidence Rates of Rheumatoid Arthritis

3. World Drug Market for Rheumatoid Arthritis 2017-2027
3.1 The Global Rheumatoid Arthritis Market, 2016
3.2 The Global RA Drugs Market: Revenue Forecast 2016-2027
3.3 The Global RA Drugs Market Segments: Revenue Forecast 2016-2027
3.4 Non-Biologics for RA
3.4.1 NSAIDs: Revenue Forecast, 2016-2027
3.4.2 Synthetic DMARDs: Revenue Forecast, 2016-2027
3.4.3 Others: Revenue Forecast, 2016-2027
3.5 Biologics for RA: Revenue Forecast 2016-2027

4. Leading Drugs in the RA Market 2017-2027
4.1 The Main Drugs in the RA Market, 2016
4.2 Humira: A Major Source of Revenue for AbbVie
4.2.1 Adalimumab Biosimilars
4.2.2 Humira: Revenue Forecast 2016-2027
4.3 Enbrel: Amgen’s Revenue Protected Until 2028
4.3.1 Etanercept Biosimilars
4.3.2 Enbrel: Revenue Forecast 2016-2027
4.4 Remicade: Facing Significant Competition from Biosimilars
4.4.1 Infliximab Biosimilars
4.4.2 Remicade: Revenue Forecast 2016-2027
4.5 Rituxan: Facing Declining Market Share
4.5.1 Rituximab Biosimilars
4.5.2 Rituxan: Revenue Forecast 2016-2027
4.6 Simponi: Market Share Remaining Stable
4.6.1 Simponi: Revenue Forecast 2016-2027
4.7 Orencia: Additional Indications Being Explored
4.7.1 Abatacept Biosimilars
4.7.2 Orencia: Revenue Forecast 2016-2027
4.8 Actemra: First IL-6R Inhibitor Approved for RA
4.8.1 Tocilizumab Biosimilars
4.8.2 Actemra: Revenue Forecast 2016-2027
4.9 Cimzia: Reliable Source of Income for UCB
4.9.1 Certolizumab Biosimilars
4.9.2 Cimzia: Revenue Forecast 2016-2027
4.10 Celebrex: Facing Generic Competition
4.10.1 Celebrex: Revenue Forecast 2016-2027
4.11 Xeljanz: Good Opportunity for Revenue Growth
4.11.1 Xeljanz: Revenue Forecast 2016-2027
4.12 Arcoxia: Sales Revenue Already Declining
4.12.1 Arcoxia: Revenue Forecast 2016-2027

5. Leading National Markets for Rheumatoid Arthritis 2016-2027
5.1 The Leading National Markets in 2016
5.2 The Leading National Markets: Comparison of Revenues and Market Shares to 2027
5.3 The Leading National Markets: Grouped Revenue Forecasts 2017-2027
5.4 The US: Prosperous Economy and Large Patient Population Enables it to dominate the RA Drugs Market
5.4.1 The US RA Drug Market: Revenue Forecast 2017-2027
5.5 Japan: Remains the Second Largest National Market
5.5.1 The RA Drug Market in Japan: Revenue Forecast 2017-2027
5.6 The EU5 Have 18% Market Share
5.6.1 The RA Drug Market in Germany: Revenue Forecast 2017-2027
5.6.2 The RA Drug Market in France: Revenue Forecast 2017-2027
5.6.3 The RA Drug Market in Italy: Revenue Forecast 2017-2027
5.6.4 The RA Drug Market in Spain: Revenue Forecast 2017-2027
5.6.5 The RA Drug Market in the UK: Revenue Forecast 2016-2026
5.7 China: Expanding Economy with Increasing Market Share
5.7.1 The RA Drug Market in China: Revenue Forecast 2017-2027
5.8 India: Expanding Population Driving Growth
5.8.1 The RA Drug Market in India: Revenue Forecast 2017-2027
5.9 Russia: Expansion Held Back by Troubled Economy
5.9.1 The RA Drug Market in Russia: Revenue Forecast 2017-2027
5.10 Brazil: Focus on Domestic Drug Manufacturing
5.10.1 The RA Drug Market in Brazil: Revenue Forecast 2017-2027

6. Rheumatoid Arthritis R&D Pipeline 2016
6.1 IL-6 Inhibitors Could Rival TNF-Inhibitors
6.1.1 Sarilumab: Already Filed With FDA
6.1.2 Sirukumab: Expected to File in Q3, 2016
6.1.3 Olokizumab: Promising Phase 2 Data
6.1.4 Clazakizumab: Alder Now Collaborating with Vitaeris
6.2 JAK Inhibitors: A Promising Class of Agents
6.2.1 Baricitinib: Potential Competitor to Xeljanz
6.2.2 Peficitinib: Selective JAK-3 Inhibitor From Astellas
6.2.3 ABT-494: Selective JAK-1 Inhibitor From AbbVie
6.2.4 Filgotinib: Following AbbVie’s Withdrawal, Galapagos Now Working with Gilead
6.3 BTK Inhibitors
6.3.1 BMS-986142: Well Tolerated in Phase 1
6.3.2 HM71224: Collaboration with Eli Lilly
6.4 GM-CSF Inhibitor
6.4.1 GSK 3196165: Potential Role in Early Disease

7. Leading Companies in the Rheumatoid Arthritis Drugs Market, 2016
7.1 Introduction to the Leading Companies
7.2 AbbVie: Secured Multiple Patents for Humira
7.3 Roche: Second-Leading Company
7.4 Johnson & Johnson: High Hopes for Sirukumab
7.5 Amgen: Enbrel Sales Protected in the US
7.6 Pfizer: Actively Developing Biosimilars
7.7 Merck & Co.: Remicade Sales in Decline
7.8 BMS: Exploring Additional Indications for Orencia
7.9 UCB: Reliant on Cimzia Revenue

8. Qualitative Analysis of the Rheumatoid Arthritis Drugs Market 2017-2027
8.1 Strengths and Weaknesses of the Rheumatoid Arthritis Market, 2017
8.1.1 Number of Elderly Patients Expected to Rise
8.1.2 Biologics Already Recognised as a Valuable Part of Treatment
8.1.3 Biologics Used in RA Often Have Multiple Indications
8.1.4 Some Patients Have an Inadequate Treatment Response
8.1.5 Efficacy of Drugs Can Diminish Over Time
8.2 Opportunities and Threats Facing the Rheumatoid Arthritis Market, 2017-2027
8.2.1 Need for Effective Drugs With Better Safety Profiles
8.2.2 Need for Less Invasive Routes of Administration
8.2.3 High Number of Products Will Saturate Market
8.2.4 Competition from Biosimilars Will Increase
8.3 Social, Technological, Economic and Political Factors Affecting the Rheumatoid Arthritis Market (STEP Analysis), 2017-2027
8.3.1 Social Factors Influencing the Rheumatoid Arthritis Market
8.3.2 Technological Factors Influencing the Rheumatoid Arthritis Market
8.3.3 Economic Factors Influencing the Rheumatoid Arthritis Market
8.3.4 Political Factors Influencing the Rheumatoid Arthritis Market
8.3.4.1 Government Pressure to Control Costs
8.3.4.2 Inter-country Variability in Biosimilar Approval Process

9. Conclusions
9.1 Global Market for RA Drugs Will Contract After 2018
9.2 Biologics Will Remain the Dominant Drug Class but their Market Share Will Drop By 10%
9.3 Enbrel Will Overtake Humira as the Leading Drug
9.4 US Will Remain the Dominant Market
9.5 Trends in the RA Drugs Market

Some Associated Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain Report Evaluation Form

List of Figures
Figure 1.1 Main Segments and Sub-Segments of the Rheumatoid Arthritis Market, 2016
Figure 3.1 The Total RA Drugs Market: Market Share (%) by Indication, 2016
Figure 3.2 The RA Drugs Market: Market Share (%) by Submarket, 2016
Figure 3.3 The Drugs Market for RA: Revenue ($m) Forecast, 2017-2027
Figure 3.4 The RA Drugs Market Segments: Revenue* ($m) Forecast, 2016-2027
Figure 3.5 The RA Drugs Market: Market Share (%) by Segment, 2021
Figure 3.6 The RA Drugs Market: Market Share (%) by Segment, 2027
Figure 3.7 Non-Biologics for RA: Revenue* ($m) Forecasts by Segment, 2016-2027
Figure 3.8 Non-Biologics for RA: Market Share (%), 2016
Figure 3.9 Non-Biologics for RA: Market Share (%), 2021
Figure 3.10 Non-Biologics for RA: Market Share (%), 2027
Figure 3.11 NSAIDs: Revenue ($m) Forecast, 2016-2027
Figure 3.12 sDMARDs: Revenue ($m) Forecast, 2016-2027
Figure 3.13 Others: Revenue ($m) Forecast, 2016-2027
Figure 3.14 Biologics for RA: Revenue ($m) Forecast, 2016-2027
Figure 4.1 The Main Drugs in the RA Market: Market Shares (%), 2016.
Figure 4.2 Humira: Revenue ($m) Forecast, 2016-2027
Figure 4.3 Enbrel: Revenue ($m) Forecast, 2016-2027
Figure 4.4 Remicade: Revenue ($m) Forecast, 2016-2027
Figure 4.5 Rituxan: Revenue ($m) Forecast, 2016-2027
Figure 4.6 Simponi: Revenue ($m) Forecast, 2016-2027
Figure 4.7 Orencia: Revenue ($m) Forecast, 2016-2027
Figure 4.8 Actemra: Revenue ($m) Forecast, 2016-2027
Figure 4.9 Cimzia: Revenue ($m) Forecast, 2016-2027
Figure 4.10 Celebrex: Revenue ($m) Forecast, 2016-2027
Figure 4.11 Xeljanz: Revenue ($m) Forecast, 2016-2027
Figure 4.12 Arcoxia: Revenue ($m) Forecast, 2016-2027
Figure 5.1 RA: Market Share (%) by Country, 2016
Figure 5.2 RA: Market Share (%) by Country, 2027
Figure 5.3 The US RA Drug Market: World Market Share (%), 2016
Figure 5.4 The US RA Drug Market: Revenue ($m) Forecast, 2016-2027
Figure 5.5 The RA Drug Market in Japan: World Market Share (%), 2016
Figure 5.6 The RA Drug Market in Japan: Revenue ($m) Forecast, 2016-2027
Figure 5.7 The EU5 RA Drug Markets: World Market Share (%), 2016
Figure 5.8 The EU5 RA Drug Markets: Revenue ($m) Forecast 2016-2027
Figure 5.9 The RA Drug Market in Germany: World Market Share (%), 2016
Figure 5.10 The RA Drug Market in Germany: Revenue ($m) Forecast 2016-2027
Figure 5.11 The RA Drug Market in France: World Market Share (%), 2016
Figure 5.12 The RA Drug Market in France: Revenue ($m) Forecast, 2016-2027
Figure 5.13 The RA Drug Market in Italy: World Market Share (%), 2016
Figure 5.14 The RA Drug Market in Italy: Revenue ($m) Forecast, 2016-2027
Figure 5.15 The RA Drug Market in Spain: World Market Share (%), 2016
Figure 5.16 The RA Drug Market in Spain: Revenue ($m) Forecast, 2016-2027
Figure 5.17 The RA Drug Market in the UK: World Market Share (%), 2016
Figure 5.18 The RA Drug Market in the UK: Revenue ($m) Forecast, 2016-2027
Figure 5.19 The RA Drug Market in China: World Market Share (%), 2016
Figure 5.20 The RA Drug Market in China: Revenue ($m) Forecast, 2016-2027
Figure 5.21 The RA Drug Market in India: World Market Share (%), 2016
Figure 5.22 The RA Drug Market in India: Revenue ($m) Forecast, 2016-2027
Figure 5.23 The RA Drug Market in Russia: World Market Share (%), 2016
Figure 5.24 The RA Drug Market in Russia: Revenue ($m) Forecast, 2016-2027
Figure 5.25 The RA Drug Market in Brazil: World Market Share (%), 2016
Figure 5.26 The RA Drug Market in Brazil: Revenue ($m) Forecast, 2016-2027
Figure 7.1 Leading Companies in the RA Drug Market: Market Share (%), 2016
Figure 7.2 AbbVie: Breakdown of Revenue (%) by RA Drug, 2016
Figure 7.3 Roche: Breakdown of Revenue (%) by RA Drug, 2016
Figure 7.4 J&J: Breakdown of Revenue (%) by RA Drug, 2016
Figure 7.5 Amgen: Breakdown of Revenue (%) by RA Drug, 2016
Figure 7.6 Pfizer: Breakdown of Revenue (%) by RA Drug, 2016
Figure 7.7 Merck & Co: Breakdown of Revenue (%) by RA Drug, 2016
Figure 7.8 BMS: Breakdown of Revenue (%) by RA Drug, 2016
Figure 7.9 UCB: Breakdown of Revenue (%) by RA Drug, 2016
Figure 9.1 RA Drugs Market: Comparison of Revenue ($m) Forecasts for Total Market* and Market for RA Indication^, 2016-2027
Figure 9.2 RA Drugs Market: Comparison of Revenue* ($m) Forecasts for Biologic and Non-Biologic Segments, 2016-2027
Figure 9.3 The Leading Drugs in the RA Market: Revenue* ($m) Forecasts, 2016, 2022, 2027
Figure 9.4 The Leading National Markets for RA Drugs: Revenue* ($m) Forecasts, 2016, 2022, 2027

List of Tables
Table 1.1 Sample
Table 2.1 Biologic Agents and Mechanism of Action
Table 2.2 Comorbidities Associated with RA in Different Organs
Table 2.3 Prevalence rate of RA in Different Countries
Table 3.1 The RA Drugs Market by Submarket, 2016
Table 3.2 The Drugs Market for RA: Revenue* ($m) Forecast, 2016-2027
Table 3.3 The RA Drugs Market Segments Forecast: Revenue* ($m), AGR (%) & CAGR (%) 2016-2027
Table 3.4 Non-Biologics for RA: Revenue* ($m) Forecasts by Segment, 2016-2027
Table 3.5 NSAIDs for RA Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027
Table 3.6 sDMARDs for RA Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027
Table 3.7 Other Drugs for RA Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027
Table 3.8 Biologics for RA Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.1 The Main Drugs in the RA Market: Revenue* ($m) and Market Share (%), 2016
Table 4.2 The Main Drugs in the RA Market Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.3 Humira: Key Facts
Table 4.4 Adalimumab Biosimilars: Current Status, 2016
Table 4.5 Humira Forecasts: Revenue* ($m), AGR (%) and CAGR (%), 2016-2027
Table 4.6 Humira: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 4.7 Enbrel: Key Facts
Table 4.8 Etanercept Biosimilars : Current Status, 2016
Table 4.9 Enbrel: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 4.10 Remicade: Key Facts
Table 4.11 Infliximab Biosimilars: Current Status, 2016
Table 4.12 Remicade: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 4.13 Rituxan: Key Facts
Table 4.14 Rituximab Biosimilars: Current Status, 2016
Table 4.15 Rituxan: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 4.16 Simponi: Key Facts
Table 4.17 Simponi: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 4.18 Orencia: Key Facts
Table 4.19 Orencia: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 4.20 Actemra: Key Facts
Table 4.21 Actemra: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 4.22 Cimzia: Key Facts
Table 4.23 Cimzia: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 4.24 Celebrex: Key Facts
Table 4.25 Celebrex: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 4.26 Xeljanz: Key Facts
Table 4.27 Xeljanz: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 4.28 Arcoxia: Key Facts
Table 4.29 Arcoxia: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 5.1 The Leading National Markets for RA: Revenue* ($m) and Market Share (%), 2016
Table 5.2 RA Drugs: Market Share (%) by Country, 2016 and 2027
Table 5.3 RA Drugs: Revenue ($m) Forecast by Country, 2016-2027
Table 5.4 The US RA Drug Market: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 5.5 The RA Drug Market in Japan: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 5.6 The EU5 RA Drug Markets: Revenue ($m) Forecast, 2016-2027
Table 5.7 The RA Drug Market in Germany: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 5.8 The RA Drug Market in France: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 5.9 The RA Drug Market in Italy: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 5.10 The RA Drug Market in Spain: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 5.11 The RA Drug Market in the UK: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 5.12 The RA Drug Market in China: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 5.13 The RA Drug Market in India: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 5.14 The RA Drug Market in Russia: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 5.15 The RA Drug Market in Brazil: Revenue ($m) and Market Share (%) Forecast, 2016-2027
Table 6.1 Pipeline R&D Products, 2016
Table 7.1 Leading Companies in the RA Drug Market: Revenue ($m) and Market Share (%), 2016
Table 7.2 AbbVie: Breakdown of Revenue ($m,%) by RA Drug, 2016
Table 7.3 Roche: Breakdown of Revenue ($m,%) by RA Drug, 2016
Table 7.4 J&J: Breakdown of Revenue ($m,%) by RA Drug, 2016
Table 7.5 Amgen: Breakdown of Revenue ($m,%) by RA Drug, 2016
Table 7.6 Pfizer: Breakdown of Revenue ($m,%) by RA Drug, 2016
Table 7.7 Merck & Co: Breakdown of Revenue ($m,%) by RA Drug, 2016
Table 7.8 BMS: Breakdown of Revenue ($m,%) by RA Drug, 2016
Table 7.9 UCB: Breakdown of Revenue ($m,%) by RA Drug, 2016
Table 8.1 Strengths and Weaknesses of the Rheumatoid Arthritis Market, 2017
Table 8.2 Opportunities and Threats Facing the Rheumatoid Arthritis Market, 2017-2027
Table 8.3 Social, Technological, Economic and Political Factors Influencing the RA Market, 2016-2026
Table 9.1 Drivers and Restraints of the RA Drugs Market, 2017-2027

★調査レポート[関節リウマチ(RA)治療薬の世界市場2017-2027] ( RHEUMATOID ARTHRITIS (RA) DRUGS MARKET 2017-2027 : Trends, Progress and Revenue Forecasting: Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra and Biosimilars; Assessment of Leading Companies Including AbbVie, Roche, J&J, Amgen, Pfizer and Merck & Co.; Prediction of Leading National Markets; and Investigation of Late-Stage R&D Including IL-6, JAK, BTK and GM-CSF Inhibitors / VGAIN712055) 販売に関する免責事項
[関節リウマチ(RA)治療薬の世界市場2017-2027] ( RHEUMATOID ARTHRITIS (RA) DRUGS MARKET 2017-2027 : Trends, Progress and Revenue Forecasting: Evaluation of Classes (Biologic DMARDs, Synthetic DMARDs) and Products Including Humira, Enbrel, Remicade, Rituxan, Actemra and Biosimilars; Assessment of Leading Companies Including AbbVie, Roche, J&J, Amgen, Pfizer and Merck & Co.; Prediction of Leading National Markets; and Investigation of Late-Stage R&D Including IL-6, JAK, BTK and GM-CSF Inhibitors / VGAIN712055) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆